Catalyst Pharmaceuticals, Inc.’s Post

DYK: 82 percent of eligible individuals are choosing not to undergo potentially life-saving lung cancer screening, according to a new study released by the American Cancer Society (ACS). Lung cancer is the country's leading cause of cancer-related deaths, with most cases not caught until a late stage when the survival rate is only 8%. When identified early, lung cancer is treatable. As early stages are largely symptom-free, its essential to follow ACS recommendation for annual screenings. Learn more about annual lung cancer screenings: https://bit.ly/3VuoPWJ

DYK: 82 percent of eligible individuals are choosing not to undergo potentially life-saving lung cancer screening, according to a new study released by the American Cancer Society (ACS). Lung cancer is the country's leading cause of cancer-related deaths, with most cases not caught until a late stage when the survival rate is only 8%. When identified early, lung cancer is treatable. As early stages are largely symptom-free, its essential to follow ACS recommendation for annual screenings. Learn more about annual lung cancer screenings: https://lnkd.in/gt8E7S7p

82% of eligible individuals are choosing not to undergo potentially life-saving lung cancer screening, according to a new study released by the American Cancer Society. Lung cancer is the country's leading cause of cancer-related deaths, with most cases not caught until a late stage when the survival rate is only 8%. When identified early, lung cancer is treatable. As early stages are largely symptom-free, its essential to follow ACS recommendation for annual screenings. Learn more about annual lung cancer screenings: https://bit.ly/4b6Df58

As much as I hate seeing myself on screen (!), I'm proud to share this post about our comprehensive lung cancer screening service at Cromwell Hospital. As a clinical oncologist specialising in lung cancer, I know how crucial early detection is. What impresses me about the Cromwell's service is how patient-centered and efficient it is - from same-day consultations and CT scans to expert radiological reporting. If any abnormalities are detected, our specialist Chest & Lung Group ensures seamless care from diagnosis through treatment. This multidisciplinary partnership brings together experts in oncology, thoracic surgery, and respiratory medicine, all working collaboratively to determine the optimal treatment path for each patient. What makes our approach unique is our ability to arrange joint consultations with multiple specialists, providing patients with a comprehensive overview of their treatment options. We also work closely with allied health professionals to deliver holistic care that maximises wellbeing throughout their treatment. For those over 55 with a history of smoking, this screening could be life-saving. Through our rapid-access service, you'll have immediate access to world-class care and a dedicated team of specialists committed to achieving the best possible outcomes. Learn more about the service in the video below. #LungCancer #CancerScreening #EarlyDetection #PatientCare #MultidisciplinaryCare https://lnkd.in/ejE6J_eE

Let’s prioritize early detection and support those affected. Together, we can save lives. 💙 #LungCancerAwareness #EarlyDetection https://lnkd.in/gfAmPASY

Small cell lung cancer (SCLC) stands as a formidable and aggressive subtype of lung cancer, notorious for its rapid growth and propensity to metastasize early. Accounting for nearly 15% of all lung cancer cases, SCLC is characterized by its quick progression, often spreading to distant organs by the time of diagnosis. This cancer type’s aggressive nature requires clinical research to identify potential treatment modalities for patients with the disease. ASTRIDE is a Phase 3 clinical trial for the treatment of extensive stage SCLC. For Additional Information: https://lnkd.in/e42_UQ6P Fosun Pharma USA Inc. #lungcancer #SCLC The Balancing Act Lifetime Television#clincialtrials Payman Darouian Stan Lechpammer, MD, Ph.D. Brian Fiske George Eliades

What Is Bladder Cancer? Bladder cancer occurs when cells in the bladder start to grow without control. Bladder cancer includes: Non-muscle-invasive bladder cancer is cancer that has not reached the muscle wall of the bladder. Most bladder cancers are non-muscle-invasive. Muscle-invasive bladder cancer is cancer that has spread through the lining of the bladder and into the muscle wall of the bladder or beyond it. Stay informed. Stay aware. 💙 #BladderCancerAwareness #KnowledgeIsPower

Carcinoid cancer is a type of slow-growing neuroendocrine tumors that form (usually) in the lungs and gastrointestinal tract. They are the most common cancer found in the appendix. November is Carcinoid Cancer Awareness Month, and it is important to highlight both how this cancer manifests, and the recent treatments for it. Learn more here: https://bit.ly/3DJlCtr

Lung cancer is by far the leading cause of cancer death. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Symptoms of lung cancer usually don't appear until the disease is already at an advanced stage. This is why regular lung cancer screening for people at high risk is so important. At age 50, talk to a doctor about your risk for lung cancer and if annual screening is right for you. Learn more: cancer.org/getscreened #ILoveYouGetScreened #GetScreenedCA #LungCancerAwarenessMonth

1 in 16 people in the U.S. will be diagnosed with lung cancer in their lifetime. At Candel, we are committed to developing our viral immunotherapy CAN-2409, as an innovative promising treatment for those suffering from lung cancer. Learn more about our progress here: https://bit.ly/4bRlBTK #WorldLungCancerDay